Localized Unresectable Thymic Carcinoma Treated with Induction Chemotherapy with Lenvatinib before Radiotherapy

Area of Science:

• Oncology
• Medical Research

Background:

• Thymic carcinoma is a rare cancer with limited therapeutic strategies.
• Lenvatinib is a targeted therapy approved for advanced thymic carcinoma.
• Induction chemotherapy prior to radiotherapy for localized, unresectable thymic carcinoma is not well-established.

Purpose of the Study:

• To evaluate the efficacy of lenvatinib as induction chemotherapy for localized, unresectable thymic carcinoma.
• To report a case of successful treatment with lenvatinib followed by radiotherapy.

Main Methods:

• A single case report of an 85-year-old Japanese woman with localized unresectable thymic carcinoma.
• Administration of lenvatinib as induction chemotherapy prior to radiotherapy.

Main Results:

• The patient received lenvatinib induction chemotherapy followed by radiotherapy.
• The findings suggest lenvatinib's potential utility in this clinical setting.

Conclusions:

• Lenvatinib may be a viable option for induction chemotherapy in localized, unresectable thymic carcinoma.
• Further investigation is warranted to confirm these findings in larger studies.